“Global Microbiome Diagnostics Market to reach a market value of USD 416.1 Million by 2030 growing at a CAGR of 17.5%”
The Global Microbiome Diagnostics Market size is expected to reach $416.1 million by 2030, rising at a market growth of 17.5% CAGR during the forecast period.
Microbiome diagnostics offer a complementary approach to traditional diagnostic modalities by providing insights into the gut microbiome’s role in metabolic health, facilitating early detection of metabolic disturbances, and stratifying individuals based on their metabolic risk profiles. Thus, the metabolic diseases segment acquired $16,399.8 thousand revenue in 2022. Metabolic diseases pose diagnostic challenges due to their multifactorial nature, heterogeneous presentation, and overlapping symptoms.
Microbiome diagnostics have applications across many healthcare areas beyond traditional fields like gastroenterology. As research progresses, the microbiome’s influence on various aspects of human health becomes increasingly apparent. It enables clinicians to develop personalized interventions, such as targeted probiotics, prebiotics, or dietary modifications, to optimize patient health outcomes.
Additionally, Technological advancements, particularly in next-generation sequencing (NGS) technologies, enable higher precision and resolution in microbiome analysis. Improved sequencing platforms and algorithms allow for detecting rare microbial taxa and subtle changes in microbial community composition, enhancing the diagnostic accuracy of microbiome tests. Hence, ongoing technological advancements in microbiome diagnostics drive the market’s growth.
Further, the COVID-19 pandemic disrupted research activities and clinical trials across various fields, including microbiome diagnostics. Many research projects and clinical studies were delayed, suspended, or canceled due to restrictions on laboratory access, reduced funding, and prioritization of COVID-19 research efforts. Some companies expanded into microbiome diagnostics to capitalize on the growing interest in this field and to meet the demand for novel diagnostic solutions. Thus, the COVID-19 pandemic moderately impacted the market.
However, the interactions between the human host and the microbiome are highly complex and dynamic, influenced by numerous factors such as genetics, diet, lifestyle, environment, and immune function. Understanding the intricate relationships between microbial communities and host physiology, metabolism, and immune responses is challenging. Thus, a limited understanding of microbiome-host interactions hampers the market’s growth.
By application, the market is divided into disease diagnostics and research application. In 2022, the disease diagnostics segment registered the largest 52.2% share in the market. It enables a precision medicine approach to disease diagnosis by assessing individual microbial profiles and their associations with specific health conditions.
The disease diagnostics segment is subdivided into gastrointestinal disorders, metabolic diseases, and others. In 2022, the gastrointestinal disorders segment attained a 49% share in the microbiome diagnostics market. Gastrointestinal disorders, including inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux disease (GERD), and colorectal cancer, affect millions of people worldwide.
Based on product, the market is bifurcated into reagents & kits and instruments. The instruments segment attained a substantial 37.2% revenue share in the market in 2022. Technological advancements have led to the development of sophisticated instruments tailored for microbiome analysis.
Based on sample, the market is categorized into fecal, saliva, skin, and others. In 2022, the fecal segment registered the highest 51.4% revenue share in the market. Fecal samples are a rich source of microbial diversity, containing diverse bacteria, fungi, viruses, and other microorganisms inhabiting the gastrointestinal tract.
On the basis of technology, the market is segmented into 16S rRNA sequencing, shot gun metagenomics, metatranscriptomics, and others. In 2022, the shot gun metagenomics segment attained a 21.4% revenue share in the market.
Based on end user, the market is divided into hospitals, academic & research institutes, and biotechnology & pharmaceutical companies. The hospitals segment attained a 49% revenue share in the market in 2022. Hospitals are primary centers for diagnosing and treating various medical conditions, including infectious diseases, chronic illnesses, and complex disorders.
Free Valuable Insights: Global Microbiome Diagnostics Market size to reach USD 416.1 Million by 2030
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed a 51% revenue share in the market in 2022. There has been increasing recognition of the microbiome’s role in human health and disease among healthcare professionals, researchers, and the general population in North America.
| Report Attribute | Details |
|---|---|
| Market size value in 2022 | USD 116.2 Million |
| Market size forecast in 2030 | USD 416.1 Million |
| Base Year | 2022 |
| Historical Period | 2019 to 2021 |
| Forecast Period | 2023 to 2030 |
| Revenue Growth Rate | CAGR of 17.5% from 2023 to 2030 |
| Number of Pages | 358 |
| Number of Tables | 620 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives |
| Segments covered | Product, Sample, Technology, Application, End User, Region |
| Country scope |
|
| Companies Included | Illumina, Inc., Becton, Dickinson and Company, Genetic Analysis AS, Microba Life Sciences Limited, BioMe Oxford Ltd, Viome Life Sciences, Inc., GoodGut S.L.U. (HIPRA, S.A.), Sun Genomics, Origin Sciences Limited, Decode Age |
By Application
By Product
By Sample
By Technology
By End User
By Geography
The Market size is projected to reach USD $416.1 million by 2030.
Ongoing technological advancements in microbiome diagnostics are driving the Market in coming years, however, High upfront cost and limited accessibility constraints restraints the growth of the Market.
Illumina, Inc., Becton, Dickinson and Company, Genetic Analysis AS, Microba Life Sciences Limited, BioMe Oxford Ltd, Viome Life Sciences, Inc., GoodGut S.L.U. (HIPRA, S.A.), Sun Genomics, Origin Sciences Limited, Decode Age
The Reagents & Kits segment is generating the highest revenue in the Market by Product in 2022; thereby, achieving a market value of $253.2 million by 2030.
The 16S rRNA Sequencing segment is leading the Market by Technology in 2022; thereby, achieving a market value of $246.9 million by 2030.
The North America region dominated the Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $203.8 million by 2030.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 